Physiological and pharmacodynamic considerations for route of EPO administration

Seminars in Nephrology

Volumn 20, Issue 4, 2000, Pages 364-374

  Besarab, Anatole ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

CELL MATURATION; DOSE CALCULATION; DRUG MECHANISM; ERYTHROID PRECURSOR CELL; ERYTHROPOIESIS; HUMAN; PRIORITY JOURNAL; REVIEW;

ANEMIA, IRON-DEFICIENCY; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROPOIETIN; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE;

EID: 0033928460     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1053/SNEP.2000.6472     Document Type: Article

References (110)

1. Bright R: Cases and observations, illustrative of renal disease accompanied with the secretion of albuminous urine. Guys Hosp Rep 1:338-379, 1836
2. Bonsdorff E, Jalavisto E: A humoral mechanism in anoxic erythrocytosis. Acta Physiol Scand 16:150-170, 1948
3. Erslev AJ: Humoral regulation of red cell production. Blood 8:349-357, 1953
4. Erslev AJ: In vitro production of erythropoietin by kidneys perfused with a serum-free solution. Blood 44:77-85,1974
5. Besarab A, Bolton VK, Browne JK, et al: The effects of normal versus anemic hematocrit on hemodialysis patients with cardiac disease. N Eng J Med 339:584-590, 1998
6. Besarab A, McCrea JB: Evolution of recombinant human erythropoietin usage in clinical practice in the United States. ASAIOJ 39:11-18, 1993
7. Besarab A, Amin N, Ahsan M, et al: Optimization of iron therapy to increase erythropoiesis in patients with end-stage renal disease. J Am Soc Nephrol 11:530-538, 2000
8. Recny MA, Scobie HA, Kim Y: Structural characterization of natural human urinary and recombinant DNA-derived erythropoietin. J Biol Chem 62:17156-17163, 1987
9. Wang FF, Kung CKF, Goldwasser E: Some chemical properties of human erythropoietin. Endocrinology 116:2286-2292, 1985
10. Dube S, Fisher JW, Powell JS: Glycosylation at specific sites of erythropoietin is essential for biosynthesis, secretion, and biological function. J Bio Chem 263:17516-17521, 1988
11. Besarab A, Flaharty KK, Erslev AJ, et al: Clinical Pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: The case for subcutaneous administration. J Am Soc Nephrol 2:1405-1416, 1992
12. Halstenson CE, Macres M, Katz SA, et al: Comparative pharmacokinetics of and pharmacody namics of epoetin alfa and epoetin beta. Clin Pharmacol Ther 50:702-712, 1991
13. Flaherty KK, Caro J, Erslev A, et al: Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy men. Clin Pharmacol Ther 47:557-564, 1990
14. Misaizu T, Atsuki S, Strickland TW, et al: Role of antennary structure of N-Iinked sugar chains in renal handling of recombinant human erythropoietin. Blood 86:4097-4104, 1995
15. McMahon FG, Vargas R, Ryan M, et al: Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood 76:1718-1722, 1990
16. Widness JA, Veng-Pedersen P, Schmidt RL, et al: In vivo 1251-erythropoietin pharmacokinetics are unchanged after anesthesia, nephrectomy and hepatectomy in sheep. J Pharmacol Exp Ther 279:1205-1210, 1996
17. Jensen JD, Madsen JK, Jensen LW, et al: Reduced production, absorption, and elimination of erythropoietin in uremia compared with healthy volunteers. J Am Soc Nephrol 5:177-185, 1994
18. Lezon CE, Martinez MP, Conti MI, et al: Plasma disappearance of exogenous erythropoietin in mice under different experimental conditions. Endocrine 8:331-333, 1998
19. Kato M, Kamiyama H, Okazaki K, et al: Mechanism for the nonlinear pharmacokinetics of erythropoietin in rats. J Pharmacol Exp Ther 283:520-527, 1997
20. Bachmann S, LeHir M, Eckard K-U: Co-localization of erythropoietin mRNA and ecto-5'-nucleotidase immunoreactivity in peritubular cells of rat renal cortex indicates that fibroblasts produce erythropoietin. J Histochem Cytochem 41:335-345, 1993
21. Maxwell PH, Osmond MK, Pugh CW, et al: Identifica- . tion of the renal erythropoietin-producing cells using transgenic mice. Kidney Int 44:1149-1162, 1993
22. Schuster S, Wilson JH, Erslev A, et al: Physiologic regulation and tissue localization of renal erythropoietin messenger RNA. Blood 70:316-18, 1988
23. Smith Dordal M, Wang FF, Goldwasser E: The role of carbohydrate in erythropoietin action. Endocrinology 116: 2293-2299, 1985
24. Wrighton NC; Farrell FX; Chang et al: Small peptides as potent mimetics of the protein hormone erythropoietin. Science 273:458-64, 1996;
25. Erslev AJ: Erythropoietin. N Engl J Med 324:1339-1344, 1991
26. Caro J, Brown S, Miller OP, et al: Erythropoietin levels in uremie nephric and anephric patients. J Lab Clin Med 93: 449-458, 1979
27. Zaroulis CHG. Hoffman BJ, Kourides IA: Serum concentration of erythropoietin measured by radioimmunoassay in hematologie disorders and chronic renal failure. Am J Hematol 11:85-92, 1981
28. Ross R, McCrea JB, Besarab A: Erythropoietin response to blood loss in hemodialysis patients is blunted but preserved. ASAIO J 40:M880-M885, 1994
29. Cahan C, Decker MJ, Arnold JL, et al: Diurnal variations in serum erythropoietin levels in healthy subjects and sleep apnea patients. J Appl Physiol 72:2112-2117, 1992
30. Müller-Wiefei D, Schärer K: Serum erythropoietin levels in children with chronic renal failure. Kidney Int 24:S70-S76, 1983 (suppl 15)
31. Goldman JM, Ireland RM, Berton-Jones M, et al: Erythropoietin concentrations in obstructive sleep apnea. Thorax 46:25-27, 1991
32. Garcia JF, Ebbe SN, Hollander L, et al: Radioimmunoassay of erythropoietin circulating levels in normal and polycythemic human being. J Lab Clin Med 99:624-635, 1982
33. Spivak JL: The mechanism of action of erythropoietin. Int J Cell Cloning 4:139-166, 1986
34. Hara H, Ogawa M: Erythropoietic precursors in mice under erythropoietic stimulation and suppression. Exp Hematol 5:141-148, 1977
35. Ogawa M, Mprter PN, Hakahata T: Renewal and commitments to differentiation of hematopoietic stem cells: an interpretive review. Blood 61:823-829, 1983
36. Ogawa M: Differentiation and proliferation of hematopoietic stem cells. Blood 81:2844-2853, 1993
37. Krause DS, Fackler MJ, Civin CI, et al: CD34: Structure, biology, and clinical utility. Blood 87:1-13, 1996
38. Spivak JL, Ferris DK, Fisher J, et al: Cell cycle-specific behavior of erythropoietin. Exper Hematol 24:141-50, 1996
39. Schuster SJ, Caro J: Erythropoietin: Physiologic basis for clinical applications. Vos Sang 65:169-170, 1993
40. Gregory CJ: Erythropoietin sensitivity as a differentiation marker in the hemopoietic system: Studies of three erythropoietic colony responses in cell culture. J Cell Physiol 89: 289-301, 1976
41. Kannourakis S, Johnson GR: Fractionation of subsets of BFU-E from normal human bone marrow: Responsiveness to erythropoietin, human placental-conditioned medium, or granulocyte-macrophage colony-stimulating factor. Blood 71:758-65, 1988
42. Sawada K, Krantz SB, Dessypris EN, et al: Human colony-forming units-erythroid do not require accessory cells but do require direct interaction with insulin-like growth factors 1 and/or insulin for erythroid development. J Clin Invest 83: 1701-1709, 1989
43. Stephenson JR, Axelrod AA, McLeod DL, et al: Induction of hemoglobin-synthesizing cells by erythropoietin in vitro. Proc Natl Acad Sei USA 65:1542-1546, 1971
44. Iscove NN: The role of erythropoietin in regulation of population size and cell cycling of early and late erythroid precursors in mouse bone marrow. Cell Tissue Kinet 10:323-334, 1977
45. Schooley JC, Garcia JF, Cantor L.N, et al. A summary of some studies on erythropoiesis using anti-erythropoietin immune serum. NY Acad Sei 149:266-280, 1968
46. Casadevall N, Dupuy E, Molho-Sabatier P, et al: Auto antibodies against erythropoietin in a patient with pure red cell aplasia. N Engl J Med 334:630-633, 1996
47. Prabhakar SS, Muhlfelder T: Antibodies to recombinant human erythropoietin causing pure red cell aplasia. Clin Nephrol 47:331-335, 1997
48. Coscarella A, Liddi R, Di Loreto M, et al: The rhGMCSF-EPO hybrid protein MEN 11300 induces anti-EPO antibodies and severe anaemia in rhesus monkeys. Cytokine 10: 964-969, 1998
49. Adamson J\V, Torok-Storb B, Lin N: Analysis of erythropoiesis by erythroid colony formation in culture. Blood Cells 4:89-103, 1978
50. D'Andrea AD, Lodish HF, Wong GG: Expression cloning of the murine erythropoietin receptor. Cell 57:277-285, 1989
51. Wong GG, Jones SS, D'Andrea AD: The molecular biology of erythropoietin receptors, in Erslev AJ, Adamson JW, Eschbach JW, Winearls CG (eds): Erythropoietin: Molecular, Cellular, and Clinical Biology. Baltimore, MD, John Hopkins University Press, 1991, pp 133-161
52. Nicola NA, Metcalf D: Subunit promiscuity among hematopoietic growth factor receptors. Cell 67:1-4, 1991
53. Bazan JF: Shared architecture of hormone binding domains in type I and type II interferon receptors. Cell 61:753754, 1990
54. Ruoslahti E: Fibronectin and its receptors. Annu Rev Biochem 57:375-413, 1988
55. Miura O, D'Andrea AD, Kabat D, et al: Induction of tyrosine phosphorylation by the erythropoietin receptor correlates with mitogenesis. Mol Cell Biol 11:4895-4902, 1991
56. Yoshimura A, Lodish HF: In vitro phosphorylation of the erythropoietin receptor and an associated protein. Mol Cell Biol 12:706-715, 1992
57. Klingmüller U, Lorenz U, Cantley LC, et al: Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell 80:729-738, 1995
58. Koury MJ, Bondurant MC: Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science 248:378-381, 1990
59. Landschutz KT, Noyes AN, Rogers O, et al: Erythropoietin receptors on murine erythroid colony-forming units: Natural history. Blood 73:1476-1486, 1989
60. Broudy VC, Lin N, Brice M, et al: Erythropoietin receptor characteristics on primary human erythroid cells. Blood 77:2283-2290, 1991
61. Sonada Y, Maekawa T, Kuzuyama Y, et al: Human interleukin-9 supports formation of a subpopulation of erythroid bursts that are responsive to interleukin-3. Am J Hematol 20: 418-424, 1992
62. Lu L, Leemhuis T, Srour EF, et al: Human interleukin-9 specifically stimulates proliferation of CD34++ DR+ + ' CD33- erythroid progenitors in normal human bone marrow in the absence of serum. Exp Hematol 21:418-424, 1992
63. Means RT, Krantz SB: Inhibition of human erythroid colony-forming units by tumor necrosis factor requires beta interferon. J Clin Invest 1992;91:416-419, 1992
64. Faquin WC, Schneider TJ, Goldberg MA: Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 79:1987-1994, 1992
65. Roodman GD, Bird A, Hatzler D, et al: Tumor necrosis factor alpha and hematopoietic progenitors: Effect of tumor necrosis factor on the growth of erythroid progenitors CFU-E and BFU-E and the hematopoietic cell lines k62, HL60, and HEL cells. Exp Hematol 15:928-935, 1987
66. Krantz SB: Erythropoietin. Blood 77:419-433, 1991
67. Eschbach JW, Egrie JC, Downing MR, et al: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of combined phase I & II clinical trials. N Engl J Med 316:73-78, 1987
68. Winearls CG, Oliver DO, Pippard MJ, et al: Effect of human erythropoietin derived from recombinant DNA on the anemia of patients maintained by chronic haemodialysis. Lancet 2:1175-1177, 1986
69. NKF-DOQI: Clinical practice guidelines for the treatment of anemia of chronic renal failure. National Kidney Foundation-Dialysis Outcomes Quality Initiative. Am J Kidney Dis 30:5192-240, 1997
70. Ma, JZ, Ebben, J, Xia H, et al: Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 10:610-619, 1999
71. Eschbach JW, Abdulhadi MH, Browne JK, et al: Recombinant human erythropoietin in anemic patients with end-stage renal disease: Results of a phase III multicenter clinical trial. Ann Intern Med 111:992-1000, 1989
72. Sabota JT: Recombinant human erythropoietin in patients with anemia due to end-stage renal disease. Contrib Nephrol 76:166-178, 1989
73. Walter J, Gal J, Taraba I: The beneficial effect of low initial dose and gradual increase of erythropoietin treatment in hemodialysis patients. Artif Organs 19:76-80, 1995
74. Eschbach JW: Erythropoietin 1991-An overview. Am J Kidney Dis 4:3-9, 1991 (suppl 1)
75. Fogh J: The increased dose response of ESF after ESF stimulation. Ann NY Acad Sei 149:217-222, 1968
76. Gurney CW, Wackman N, Filmanowitz E: Studies on erythropoiesis. XVII. Some quantitative aspects of the erythropoietic response to erythropoietin. Blood 17:531-546, 1961
77. Veng-Pedersen P, Widness JA, Pereira LM, et al: Kinetic evaluation of nonlinear drug elimination by a disposition decomposition analysis. Application to the analysis of the nonlinear elimination kinetics of erythropoietin in adult humans. J Pharm Sei 84:760-767, 1995
78. Spivak JL, Hogans BB: The in vivo metabolism of recombinant human erythropoietin in the rat. Blood 73:90-99, 1989
79. Piroso E, Flaherty KK, Caro J, Erslev AJ: Erythropoietin half-life in rats with hypoplastic and hyperplastic bone marrows. Blood 74:270, 1989 (abstr)
80. Naets JP, Wittek M: Effect of erythroid hyperplasia on the disappearance rate of erythropoietin in the dog. Acta Haematol 39:42-50, 1968
81. Montini G, Zacchello G, Perfumo F, et al: Pharmacokinetics and hematologie response to subcutaneous administration of recombinant human erythropoietin in children undergoing long-term peritoneal dialysis: A multtcenter study. J Pediatr 122:297-302, 1993
82. Hughes RT, Cotes PM, Oliver DO, et al: Correction of anemia of chronic renal failure with erythropoietin: Pharmacokinetic studies in patients on hemodialysis and CAPD. Contrib Nephrol 76:122-130, 1989
83. Salmonson T: Pharmacokinetic and pharmacodynamic studies on recombinant human erythropoietin. Scand J Urol Nephrol 129:1-66, 1990 (suppl)
84. Nielsen OJ: Pharmacokinetics of recombinant human erythropoietin in chronic haemodialysis patients. Pharmacol Toxicol 66:83-86, 1990
85. Lui SF, Chung \VW, Leung CB, et al: Pharmacokinetics and pharmacodynamics of subcutaneous and intraperitoneal administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Clin Nephrol 33:47-51, 1990
86. Gladziwa U, Klotz U, Baumer Ket al: Pharmacokinetics of epoetin (recombinant human erythropoietin) after long term therapy in patients undergoing haemodialysis and haemofiltration. Clin Pharmacokin 25:145-53, 1993
87. Besarab A, Nasca T, ROSS R: Erythropoietin in patients prior to end-stage renal disease. Curr Opin Nephrol Hyperten 4:155-161, 1995
88. Brockmoller J, Kochling J, Weber W, et al: The pharmacokinetics and pharmacodynamics or recombinant human erythropoietin in hemodialysis patients. Br J Clin Pharmacol 34:449-508, 1992
89. Albitar S, Meulders Q, Hammond H, et al: Subcutaneous versus intravenous administration of erythropoietin improves its efficacy for the treatment of anaemia in haemodialysis patients. Nephrol Dial Transplant 10:40-43, 1995
90. Parker KP, Mitch WE, Stivelman JC, et al. Safety and efficacy of low dose subcutaneous erythropoietin in hemodialysis patients. J Am Soc Nephrol 8:288-93, 1997
91. Grannolleras C, Branger B, Beau MC, et al: Experience with daily self-administered subcutaneous erythropoietin. Contrib Nephrol 76:143-148, 1989
92. Granneloras C, Branger B, Shaldon S, et al: Subcutaneous erythropoietin: A comparison of daily and thrice weekly administration. Contrib Nephrol 88:144-151, 1991
93. Hood VL, Ingraham A: Erythropoietin for continuous ambulatory peritoneal dialysis patients: Once a week can be enough. J Am Soc Nephrol 2:1545-1546, 1992
94. Sohmiya M, Kabika T, Kalo Y: Therapeutic use of continued subcutaneous infusion of recombinant human erythropoietin in malnourished predialysis anemic patients with diabetic nephropathy. Eur J Endocrinol 139:367-370, 1998
95. Boelaert JR, Schurgers ML, Matthys EV, et al: Comparative pharmacokinetics of recombinant erythropoietin administered by the intravenous, subcutaneous, and intraperitoneal routes in continuous ambulatory peritoneal dialysis (CAPD) patients. Perit Dial Int 9:95-98, 1989
96. Kampf D, Kahl A, Passlick J, et al: Single dose kinetics or recombinant human erythropoietin after intravenous subcutaneous and intraperitoneal administration. Contrib Nephrol 76:106-111, 1989
97. Macdougall IC, Roberts DE, Neubert P, et al: Pharmacokinetics of intravenous, intraperitoneal, and subcutaneous recombinant erythropoietin in patients on CAPD. Contrib Nephrol 76:1121-1126, 1989
98. Neumayer H-H, Brockmoller J, Fritschka, et al: Pharmacokinetics of recombinant human erythropoietin after subcutaneous administration and in long-term IV treatments in patients on maintenance hemodialysis. Contrib Nephrol 76:131-142, 1989
99. Hörl WH: Optimal route of administration of erythropoietin in chronic renal failure patients: Intravenous versus subcutaneous. Acta Haematoligica 87:16-19, 1992 (suppl 1)
100. Brahm M: Subcutaneous treatment with recombinant human erythropoietin-The influence of injection frequency and skin-fold thickness. Scand J Urol Nephrol 33:192-166, 1999
101. Taylor JE, Belch JJF, Fleming LAV, et al: Erythropoietin response and route of administration. Clin Nephrol 41:297-302, 1994
102. Kaufman JS, Reda DJ, Fye CI, et al: Subcutaneous compared to intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis patients. N Engl J Med 339:578-583, 1998
103. St Peter WL, Lewis MJ, Macres MG: Pain comparison after subcutaneous administration of single-dose formulations versus multidose formulation of epogen in hemodialysis patients. Am J Kidney Dis 32:470-474, 1998
104. Peterson J, Kang, MS, Hays MT: Erythropoietin can be administered during dialysis: A kinetic analysis. ASAIO J 42: 27-33, 1996
105. Bargman JM, Jones JE, Petro JM: The pharmacokinetics of intraperitoneal erythropoietin administered undiluted or diluted in dialysate. Perit Dial Int 12:369-372, 1992
106. Moriya H, Maitani, Y, Shimoda N, et al: Pharmacokinetic and pharmacological profiles of free and liposomal recombinant human erythropoietin after intravenous and subcutaneous administration in rats. Pharm Res 14:1621-1628, 1997
107. Maitani Y, Moriya H, Shimoda N, et al: Distribution characteristics of entrapped recombinant human erythropoietin in liposomes and its intestinal absorption in rats. Int J Pharm 185:13-22, 1999
108. Mitragotri S, Blakschtein D, Langer R: Utrasoundmediated transdermal protein delivery. Science 269:850-853, 1995
109. Elliott SD, Lorenzini T, Chang D, et al: Mapping of the active site of recombinant human erythropoietin. Blood 89:493-502, 1997
110. Sytkowski AJ, Lunn ED, Risinger MA, Davis KL. An erythropoietin fusion protein comprised of identical repeating domains exhibits enhanced biological properties. J Biol Chem 274:24773-24773-24778, 1999